{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"India Tech Report","title":"Muon and Rocket Lab’s launches, Krystal Biotech’s gene therapy, SunHydrogen’s pilot, EKA Mobility, and more","html":"","width":"100%","height":180,"duration":335,"description":"Daily brief on deep tech and climate tech news in India and around the world\nEKA Mobility has raised fresh funding to expand its capacity. Image courtesy company website.\nMuon Space launches Hydrosat’s VanZyl-2 mission with advanced climate data capabilities \nMuon Space has successfully launched Hydrosat’s VanZyl-2 mission, marking the fourth deployment of its HALO spacecraft platform. This mission aims to deliver high-resolution thermal infrared data for climate and agricultural monitoring.\nThe VanZyl-2 satellite will enhance Hydrosat’s ability to provide critical insights into water stress, drought, and crop health, supporting efforts to address climate change and improve food security worldwide.\nListen to the podcast\n\nRocket Lab adjusts Electron mission manifest to include HawkEye\nRocket Lab has adjusted its Electron launch manifest to deploy the “Get The Hawk Outta Here” mission for geospatial analytics firm HawkEye 360, launching in two days from New Zealand. The mission will deliver four satellites focused on collecting and geolocating radio frequency signals for global security.\nThe rocket was scheduled to launch the ‘Symphony in the Stars’ mission on Tuesday.\nSatellogic to deliver next-generation satellite for Malaysia’s earth observation programme\nSatellogic is set to provide its next-generation satellite and technology transfer services for Malaysia’s national earth observation satellite program. This partnership will enhance Malaysia’s capabilities in satellite imaging, supporting applications in environmental monitoring, agriculture, and national security.\nKrystal Biotech begins phase 3 trial for KB803 in treating corneal abrasions\nKrystal Biotech has dosed the first patient in its Phase 3 clinical trial of KB803, a gene therapy for treating and preventing corneal abrasions in patients with dystrophic epidermolysis bullosa (DEB). This trial aims to evaluate the safety and efficacy of KB803, which could become the first approved treatment for corneal...","thumbnail_url":"https://img.transistorcdn.com/klwtZi6_OVxR1RQx-EUqBBLq9JNmkk2p0xt3ov7-eeg/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9kYjRi/MTNkNDVhMTVlOThm/MDM4ZmVlYjFmZGNl/OGFiNy5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}